F2G is an
established UK Biotech focussing on the discovery and development of novel
drugs to treat life threatening fungal diseases. Fungal infection typically
affects the immune-compromised patient where mortality rates are often
very high. This patient population is increasing year by year due to increased
cases of cancer, organ transplants and the use of potent medicines that
affect the immune system. As a result serious fungal infections continue
The focus at F2G is to serve the current unmet medical need by developing
drugs that target the most difficult to treat fungi, especially those
with the highest mortality rates.
Through its proprietary genomics technology and antifungal screening activities
F2G has identified a number of novel chemical series with potent antifungal
activity. These novel series form the basis of the F2G development pipeline.
Currently F2G is advancing its F3 series of anti mould compounds. This
is a novel class of antifungal agent, which acts through a completely
new mechanism different from all currently marketed drugs. The F3 series
displays highly potent activity against clinically relevant aspergilli
and many other important pathogenic moulds.
F2G has a dedicated team of experienced scientists from a wide variety
of research and drug development backgrounds supported by an experienced
management group with many years experience of drug development within
the Pharmaceutical industry.
Ltd, Lankro Way, Eccles, Manchester, M30 0LX
Tel +44 (0)161 785 1270 Fax +44 (0)161 785 1273 Email firstname.lastname@example.org